Mechanism of action
It is a relatively selective inhibitor of peak III cyclic AMP phosphodiesterase isozyme in cardiac and vascular muscle. In patients with CHF, it produces dose related and plasma drug concentration related increases in the maximum rate of increase of left ventricular pressure. Milrinone has a direct inotropic and direct arterial vasodilator activity.